2025, Confidentiality, Marketing and Patent Application

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2025

Confidentiality

Marketing

Patent Application

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. and Alexion Pharmaceuticals Inc. an eculizumab product.

Marketing

Marketing Marketing Settlement Patent

How plausible may be a conference on IP (and regulatory) exclusivity? Sufficiently

The IPKat

NOVEMBER 14, 2022

The latter, contrary to what it might appear from its date of adoption (2014), is a regulation that is certainly topical, having started to take effect as of 31 July 2022, with a transitional period that will last until 31 January 2025, but which will see a first and fundamental provision entering into force on 31 January 2023.

IP Marketing Marketing Confidentiality

Intellectual Property Pulse

Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry

How plausible may be a conference on IP (and regulatory) exclusivity? Sufficiently

Stay Connected